New and emerging pharmacologic treatments for MDD. [PDF]
Uyar A, Gonul AS.
europepmc +1 more source
Cancer Pain Is Not One-Size-Fits-All: Evolving from Tradition to Precision. [PDF]
Shapoo N +4 more
europepmc +1 more source
Renal Implications of Kappa Opioid Receptor Signaling in Sprague-Dawley Rats. [PDF]
Didik S +11 more
europepmc +1 more source
A New Trick of Old Dogs: Can Kappa Opioid Receptor Antagonist Properties of Antidepressants Assist in Treating Treatment-Resistant Depression (TRD)? [PDF]
Schreiber S, Keidan L, Pick CG.
europepmc +1 more source
Sex-specific genetics underlie increased chronic pain risk in women: decoding the genetic architecture of chronic pain. Comment on Br J Anaesth 2025; 135: 401-5. [PDF]
Zeng J, Zhou Z.
europepmc +1 more source
Seeing the bigger picture: endogenous opioids mediate attentional broadening after reward receipt. [PDF]
van Steenbergen H +5 more
europepmc +1 more source
Targeting the kappa opioid receptor for analgesia and antitumour effects. [PDF]
Lambert DG, Mincer JS.
europepmc +1 more source
Related searches:
Antagonists of the kappa opioid receptor
Bioorganic & Medicinal Chemistry Letters, 2014The research community has increasingly focused on the development of OPRK antagonists as pharmacotherapies for the treatment of depression, anxiety, addictive disorders and other psychiatric conditions produced or exacerbated by stress. Short-acting OPRK antagonists have been recently developed as a potential improvement over long-acting prototypic ...
Mariangela, Urbano +3 more
openaire +2 more sources

